Research ArticleArticle
Characterization of Agonist-Induced Motilin Receptor Trafficking and Its Implications for Tachyphylaxis
Vahideh Lamian, Adam Rich, Zhengping Ma, James Li, Ramakrishna Seethala, David Gordon and Yves Dubaquie
Molecular Pharmacology January 2006, 69 (1) 109-118; DOI: https://doi.org/10.1124/mol.105.017111
Vahideh Lamian
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)
Adam Rich
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)
Zhengping Ma
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)
James Li
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)
Ramakrishna Seethala
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)
David Gordon
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)
Yves Dubaquie
Clinical Discovery Technologies (V.L., Y.D.), Metabolic Disease Research (Z.M., R.S., D.G.), Discovery Chemistry (J.L.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey; and Biological Sciences, State University of New York—Brockport, Brockport, New York (A.R.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Characterization of Agonist-Induced Motilin Receptor Trafficking and Its Implications for Tachyphylaxis
Vahideh Lamian, Adam Rich, Zhengping Ma, James Li, Ramakrishna Seethala, David Gordon and Yves Dubaquie
Molecular Pharmacology January 1, 2006, 69 (1) 109-118; DOI: https://doi.org/10.1124/mol.105.017111
Research ArticleArticle
Characterization of Agonist-Induced Motilin Receptor Trafficking and Its Implications for Tachyphylaxis
Vahideh Lamian, Adam Rich, Zhengping Ma, James Li, Ramakrishna Seethala, David Gordon and Yves Dubaquie
Molecular Pharmacology January 1, 2006, 69 (1) 109-118; DOI: https://doi.org/10.1124/mol.105.017111
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement